公开(公告)号：US20250066509A1

公开(公告)日：2025-02-27

申请号：US18724948

申请日：2022-12-29

Applicant: SHANGHAI JMT-BIO TECHNOLOGY CO., LTD.

Inventor： Xu FENG ,  Liping SONG ,  Yi FAN ,  Yali MENG

IPC: C07K16/40 ,  A61K39/00 ,  A61K47/68 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10

Abstract: Provided are an anti-βKlotho antibody and the use thereof. The anti-βKlotho antibody can be used for treating βKlotho-mediated or βKlotho-FGFR1c-FGF21-mediated diseases, especially abnormal metabolic diseases, such as type 1 diabetes, type 2 diabetes, dyslipidemia, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), cardiovascular disease, metabolic syndrome or obesity.

公开(公告)号：US20250066496A1

公开(公告)日：2025-02-27

申请号：US18940209

申请日：2024-11-07

Applicant: Dyne Therapeutics, Inc.

Inventor： Romesh R. Subramanian ,  Mohammed T. Qatanani ,  Timothy Weeden

IPC: C07K16/28 ,  A61K47/68 ,  A61P21/00 ,  C12N15/113

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

公开(公告)号：US20250066477A1

公开(公告)日：2025-02-27

申请号：US18726347

申请日：2023-01-04

Applicant: Inhibrx Biosciences, Inc.

Inventor： Bryan R. Becklund ,  Kyle S. Jones ,  Kaitlyn N. Robinson ,  Andrew M. Eckles ,  John C. Timmer ,  Brendan P. Eckelman

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30

Abstract: Provided herein are VHH-containing polypeptides that bind γδ T-cells. Uses of the VHH-containing polypeptides are also provided.

公开(公告)号：US20250066468A1

公开(公告)日：2025-02-27

申请号：US18734619

申请日：2024-06-05

Applicant: L.E.A.F. HOLDINGS GROUP LLC

Inventor： Clet NIYIKIZA ,  Jose VARGHESE

IPC: C07K16/28 ,  A61K9/00 ,  A61K9/08 ,  A61K9/127 ,  A61K9/19 ,  A61K31/519 ,  A61K45/06 ,  A61K47/68 ,  A61K47/69

Abstract: The disclosure provides a liposomal antifolate composition comprising a liposome including an interior space, a bioactive antifolate agent disposed within said interior space, a steric stabilizer attached to an exterior of the liposome, and a targeting moiety comprising a protein with specific affinity for at least one folate receptor, said targeting moiety attached to at least one of the steric stabilizer and the exterior of the liposome.

公开(公告)号：US20250064961A1

公开(公告)日：2025-02-27

申请号：US18920375

申请日：2024-10-18

Applicant: AbbVie Biotherapeutics Inc.

Inventor： Adrian D. Hobson ,  Christopher C. Marvin ,  James W. Purcell

IPC: A61K47/68 ,  A61P35/00

Abstract: The present disclosure provides anti-CD19 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

公开(公告)号：US20250057972A1

公开(公告)日：2025-02-20

申请号：US18896790

申请日：2024-09-25

Applicant: Dyne Therapeutics, Inc.

Inventor： Timothy Weeden ,  Scott Hilderbrand ,  Sean Spring ,  Peiyi Shen ,  Cody A. Desjardins ,  Romesh R. Subramanian ,  Mohammed T. Qatanani ,  Brendan Quinn ,  John Najim

IPC: A61K47/68 ,  A61K47/54 ,  A61K47/65 ,  A61P21/00

Abstract: Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes (e.g., wherein each complex is of the exemplary formula shown below) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody). In some embodiments, the complexes are formulated with histidine (e.g., L-histidine) and sucrose at a specified pH (e.g., about 5.0 to 7.0). Also provided are uses of these formulations for treating a subject having a mutated DMD allele associated with Duchenne Muscular Dystrophy.

公开(公告)号：US20250057969A1

公开(公告)日：2025-02-20

申请号：US18804226

申请日：2024-08-14

Applicant: AstraZeneca AB

Inventor： Jonathan David BEADLE ,  Albano GALAN COCA ,  Mattia COCCO ,  William Robert Fraser GOUNDRY

IPC: A61K47/68 ,  A61P35/00

Abstract: The specification relates to conjugates comprising a linker of Formula (IA): and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.

公开(公告)号：US12226490B2

公开(公告)日：2025-02-18

申请号：US18349337

申请日：2023-07-10

Applicant: Sutro Biopharma, Inc.

Inventor： Amandeep Gakhal ,  Abigail Yu ,  Ryan Stafford ,  Jeffrey Hanson ,  Alice Yam ,  Krishna Bajjuri ,  Andreas Maderna ,  Cristina Abrahams ,  Xiaofan Li ,  Gang Yin ,  Miao Wen ,  Kristin Bedard ,  Daniel Calarese ,  Helena Kiefel

IPC: A61K47/68 ,  A61K31/502 ,  A61P35/00

Abstract: The present disclosure relates to antibodies and antibody conjugates, for instance antibody drug conjugates, with binding specificity for receptor tyrosine kinase orphan receptor 1 (ROR1) and its isoforms and homologs, and compositions comprising the antibodies or antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibodies and antibody conjugates and compositions thereof as well as methods of using the antibodies and antibody conjugates and compositions thereof, such as in therapeutic and diagnostic methods.

公开(公告)号：US20250051770A1

公开(公告)日：2025-02-13

申请号：US18723163

申请日：2022-12-20

Applicant: SAPREME TECHNOLOGIES B.V.

Inventor： Miriam Verena BUJNY ,  Ruben POSTEL ,  Guy HERMANS

IPC: C12N15/113 ,  A61K31/704 ,  A61K36/185 ,  A61K47/54 ,  A61K47/61 ,  A61K47/64 ,  A61K47/68 ,  A61P21/00

Abstract: The invention lies in the field of treatment and prophylaxis of muscle wasting disorders, in particular the ones involving a genetic factor that can be targeted by a delivery of a therapeutic nucleic acid into the muscle cells. In line with the latter aspect, disclosed herein are pharmaceutical compositions and advantageous components thereof that substantially enhance the effective delivery and release of a therapeutic nucleic acid into the right internal compartment of the muscle cell, such as the cytosol and/or the nucleus, in which compartment it can reach and act upon its genetic target. As disclosed herein, this substantially enhanced delivery and release is achieved by a provision of an endosomal-escape-enhancing saponin in the disclosed herein pharmaceutical compositions comprising therapeutic nucleic acids and, optionally, muscle cell-targeting ligands conjugated therewith. As for the first time demonstrated herein, these saponin types not only surprisingly retain their endosomal-escape-enhancing properties in fully differentiated muscle cells but also can in an unconjugated state successfully be delivered thereto together with the therapeutic nucleic acids.

公开(公告)号：US20250051475A1

公开(公告)日：2025-02-13

申请号：US18719725

申请日：2022-12-30

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Azra RAZA ,  Abdullah M. ALI

IPC: C07K16/30 ,  A61K47/68 ,  C07K16/28 ,  G01N33/574

Abstract: The subject matter described herein relates to a method of treating cancer in a subject in need thereof using a bispecific molecule recognizing two antigen markers of different tissue lineages on the surface of The First Cell.